• Received positive FDA feedback on Phase 2b trial design for lead candidate amsulostat in myelofibrosis
• Completed recruitment in Phase 2 trial of SNT-4728 for isolated REM Sleep Behaviour Disorder, top-line results expected Q2 CY26
• Garvan Institute secures $3 million MRFF grant to advance amsulostat in pancreatic cancer, no cash contribution from Syntara

Syntara Limited, a clinical-stage drug development company, provided a summary of its activities for the quarter ended 31 March 2026. Key highlights include:- Received positive feedback from the US FDA after a Type C meeting, supporting the Phase 2b trial design for lead candidate amsulostat in the treatment of myelofibrosis. The Phase 2b study will be a double-blind, placebo-controlled study of amsulostat added to standard of care for patients who have had an inadequate response.- Completed recruitment into the randomised, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD). Top-line results are expected in Q2 CY26. iRBD is a strong clinical predictor of neurodegenerative diseases like Parkinson's.- The Garvan Institute of Medical Research was awarded a $3 million MRFF grant to conduct two multicentre clinical studies in advanced pancreatic cancer, one of which will evaluate Syntara's amsulostat in combination with standard-of-care chemotherapy. Syntara will contribute drug supply and expertise, with no cash funding required.- Received a $1.7 million milestone payment from Parkinson's UK related to the SNT-4728 Phase 2 trial. Syntara is eligible for a further $0.45 million upon project completion.- Announced a capital raising of $8 million via a two-tranche institutional placement, and a $2 million share purchase plan, to fund clinical trial readouts, licensing discussions, and preparatory work for the amsulostat Phase 2b study.

The company expects five clinical data readouts during calendar year 2026 across its pipeline.

With five clinical data readouts expected in 2026 and new funding, Syntara is well positioned to deliver a transformative year.